当前位置: 首页» 科研进展» 最新论文

最新论文

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus.Vaccines (Basel).2021 Feb 10;9(2):142.doi: 10.3390/vaccines9020142.

Yulong Wang,Nan Jiang,Linjin Fan ,Li Gao ,Kai Li,Yulong Gao,Xinxin Niu,Wenying Zhang,Hongyu Cui,Aijing Liu,Qing Pan,Changjun Liu,Yanping Zhang,Xiaomei Wang,Xiaole Qi

 

Vaccines (Basel).2021 Feb 10;9(2):142.doi: 10.3390/vaccines9020142.

 

Abstract

Infectious bursal disease (IBD), an immunosuppressive disease of young chickens, is caused by infectious bursal disease virus (IBDV). Novel variant IBDV (nVarIBDV), a virus that can evade immune protection against very virulent IBDV (vvIBDV), is becoming a threat to the poultry industry. Therefore, nVarIBDV-specific vaccine is much needed for nVarIBDV control. In this study, the VP2 protein of SHG19 (a representative strain of nVarIBDV) was successfully expressed using an Escherichia coli expression system and further purified via ammonium sulfate precipitation and size-exclusion chromatography. The purified protein SHG19-VP2-466 could self-assemble into 25-nm virus-like particle (VLP). Subsequently, the immunogenicity and protective effect of the SHG19-VLP vaccine were evaluated using animal experiments, which indicated that the SHG19-VLP vaccine elicited neutralization antibodies and provided 100% protection against the nVarIBDV. Furthermore, the protective efficacy of the SHG19-VLP vaccine against the vvIBDV was evaluated. Although the SHG19-VLP vaccine induced a comparatively lower vvIBDV-specific neutralization antibody titer, it provided good protection against the lethal vvIBDV. In summary, the SHG19-VLP candidate vaccine could provide complete immune protection against the homologous nVarIBDV as well as the heterologous vvIBDV. This study is of significance to the comprehensive prevention and control of the recent atypical IBD epidemic.

Keywords: novel variant infectious bursal disease virus; vaccine; viral-like particle.

 

扫一扫 关注我
网站首页 联系我们
TOP